TITLE:
Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea

CONDITION:
Diabetes Mellitus

INTERVENTION:
FK614

SUMMARY:

      The purpose of the study is to assess the safety and efficacy of FK614 in type 2 diabetic
      subjects receiving sulfonylurea (SU) monotherapy.
    

DETAILED DESCRIPTION:

      This is a prospective randomized, double-blind, placebo controlled, parallel group, Phase 2
      study. Subjects meeting selection criteria will be randomly assigned to receive 12 weeks
      twice daily (BID) dosing with FK614 or placebo. Enrollment for this study will be
      approximately 200 patients.
    

ELIGIBILITY:
Gender: All
Age: 25 Years to 70 Years
Criteria:

        Inclusion Criteria

          -  Has history of type 2 diabetes mellitus for at least 1 year

          -  Has been taking current sulfonylurea (SU) for at least 3 months. Subjects currently
             taking metformin may be eligible to be switched.

          -  Has not received any oral antidiabetic medication other than an SU or taken regularly
             prescribed insulin for at least 3 months

        Exclusion Criteria

          -  Has type 1 diabetes mellitus

          -  Has uncontrolled hypertension, i.e., systolic BP >170 or diastolic BP > 95 mm Hg.

          -  History of congestive heart failure
      
